Merck KGaA to Acquire Bio-Techne for $73/Share in Cash, 5.8% Premium
TECH sits 60% above its 52-week low of $43.195.
Summary
Merck KGaA has announced its intent to acquire Bio-Techne for $73 per share in an all-cash transaction. This offer represents a 5.8% premium over Bio-Techne's current trading price of $69.00 and is above its 52-week high of $72.16. The acquisition follows recent news of activist investor Ananym urging Bio-Techne to explore a sale. This definitive M&A event provides a significant premium for shareholders and fundamentally alters the investment outlook for Bio-Techne.
At the time of this announcement, TECH was trading at $69.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $43.20 to $72.16. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Dow Jones Newswires.